Pluripotent stem cell-derived natural killer cells for cancer therapy

Translational Research

Volumn 156, Issue 3, 2010, Pages 147-154

  Knorr, David A ^a   Kaufman, Dan S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; KRUPPEL LIKE FACTOR 4; LIN28; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER THERAPY; CD25+ T LYMPHOCYTE; CELL MATURATION; CELL POPULATION; EMBRYONIC STEM CELL; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; KIDNEY CARCINOMA; LIFESPAN; LYMPHOCYTE; MELANOMA; NATURAL KILLER CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANIMAL MODEL; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; KIDNEY NEOPLASMS; MOUSE; NEOPLASMS; PHYSIOLOGY; PROCEDURES; SPINAL CORD INJURIES; TRANSPLANTATION;

ANIMALS; B-LYMPHOCYTES; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTES; MELANOMA; MICE; MODELS, ANIMAL; NEOPLASMS; PLURIPOTENT STEM CELLS; SPINAL CORD INJURIES; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 77956254822     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2010.07.008     Document Type: Review

References (79)

1. E.D. Thomas Bone marrow transplantation: a review Semin Hematol 36 1999 95 103
2. J.A. Thomson, J. Itskovitz-Eldor, and S.S. Shapiro Embryonic stem cell lines derived from human blastocysts Science 282 1998 1145 1147
3. H.S. Keirstead, G. Nistor, and G. Bernal Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury J Neurosci 25 2005 4694 4705
4. N. Akira, K. Umeda, and H. Chang Orderly hematopoietic development of induced pluripotent stem cells via Flk-1+ hemoangiogenic progenitors J Cell Physiol 221 2009 367 377
5. Z. Ye, H. Zhan, and P. Mali Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders Blood 114 2009 5473 5480
6. K.-D. Choi, J. Yu, and K. Smuga-Otto Hematopoietic and endothelial differentiation of human induced pluripotent stem cells Stem Cells 27 2009 559 567
7. I.-H. Park, N. Arora, and H. Huo Disease-specific induced pluripotent stem cells Cell 134 2008 877 886
8. D.S. Kaufman Toward clinical therapies utilizing hematopoietic cells derived from human pluripotent stem cells Blood 114 2009 3513 3523
9. D.S. Kaufman, E.T. Hanson, R.L. Lewis, R. Auerbach, and J.A. Thomson Hematopoietic colony-forming cells derived from human embryonic stem cells Proc Natl Acad Sci U S A 98 2001 10716 10721
10. X. Tian, J.K. Morris, J.L. Linehan, and D.S. Kaufman Cytokine requirements differ for stroma and embryoid body-mediated hematopoiesis from human embryonic stem cells Exp Hematol 32 2004 1000 1009
11. M.A. Vodyanik, J.A. Bork, J.A. Thomson, and I.I. Slukvin Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential Blood 105 2005 617 626
12. K.D. Choi, M.A. Vodyanik, and I.I. Slukvin Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors J Clin Inves 119 2009 2818 2829
13. P.S. Woll, C.H. Martin, J.S. Miller, and D.S. Kaufman Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity J Immunol 175 2005 5095 5103
14. Z. Galic, S.G. Kitchen, and A. Kacena T lineage differentiation from human embryonic stem cells Proc Natl Acad Sci U S A 103 2006 11742 11747
15. X. Tian, M.K. Hexum, V.R. Penchev, R.J. Taylor, L.D. Shultz, and D.S. Kaufman Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34+ cells preferentially develop into endothelial cells Stem Cells 27 2009 2675 2685
16. X. Tian, P.S. Woll, J.K. Morris, J.L. Linehan, and D.S. Kaufman Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity Stem Cells 24 2006 1370 1380
17. M.H. Ledran, A. Krassowska, and L. Armstrong Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches Cell Stem Cell 3 2008 85 98
18. A.D. Narayan, J.L. Chase, and R.L. Lewis Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients Blood 107 2006 2180 2183
19. L. Wang, P. Menendez, and F. Shojaei Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression J Exp Med 201 2005 1603 1614
20. C. Lengerke, M. Grauer, and N.I. Niebuhr Hematopoietic development from human induced pluripotent stem cells Ann N Y Acad Sci 1176 2009 219 227
21. K.H. Chang, A. Huang, R.K. Hirata, P.R. Wang, D.W. Russell, and T. Papayannopoulou Globin phenotype of erythroid cells derived from human induced pluripotent stem cells Blood 115 2010 2553 2554
22. A. Giorgetti, N. Montserrat, I. Rodriguez-Piza, C. Azqueta, A. Veiga, and J.C. Izpisúa Belmonte Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2 Nat Protoc 5 2010 811 820
23. K. Takahashi, and S. Yamanaka Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors Cell 126 2006 663 676
24. J. Yu, M.A. Vodyanik, and K. Smuga-Otto Induced pluripotent stem cell lines derived from human somatic cells Science 318 2007 1917 1920
25. M. Wernig, A. Meissner, and R. Foreman In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state Nature 448 2007 318 324
26. I.H. Park, R. Zhao, and J.A. West Reprogramming of human somatic cells to pluripotency with defined factors Nature 451 2008 141 146
27. X.Y. Zhao, W. Li, and Z. Lv iPS cells produce viable mice through tetraploid complementation Nature 461 2009 86 90
28. K. Takahashi, K. Tanabe, and M. Ohnuki Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 131 2007 861 872
29. J. Yu, K. Hu, and K. Smuga-Otto Human induced pluripotent stem cells free of vector and transgene sequences Science 324 2009 797 801
30. C.A. Sommer, A.G. Sommer, and T.A. Longmire Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector Stem Cells 28 2010 64 74
31. A. Raya, I. Rodríguez-Piz, and G. Guenechea Disease-corrected haematopoietic progenitors from Fanconi Anemia induced pluripotent stem cells Nature 460 2009 53 59
32. A. Urbach, O. Bar-Nur, G.Q. Daley, and N. Benvenisty Differential modeling of Fragile X Syndrome by human embryonic stem cells and induced pluripotent stem cells Cell Stem Cell 6 2010 407 411
33. J.E. Carette, J. Pruszak, and M. Varadarajan Generation of iPSCs from cultured human malignant cells Blood 115 2010 4039 4042
34. R. Maehr, S. Chen, and M. Snitow Generation of pluripotent stem cells from patients with type 1 diabetes Proc Natl Acad Sci U S A 106 2009 15768 15773
35. A.C. Hayday, and M. Peakman The habitual, diverse and surmountable obstacles to human immunology research Nat Immunol 9 2008 575 580
36. M.M. Davis A prescription for human immunology Immunity 29 2008 835 838
37. J. Mestas, and C.C. Hughes Of mice and not men: differences between mouse and human immunology J Immunol 172 2004 2731 2738
38. M.A. Caligiuri Human natural killer cells Blood 112 2008 461 469
39. T.J. Nathalie, and H.R. David Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells Immunol Rev 224 2008 85 97
40. A.H. Jonsson, W.M. Yokoyama, and W.A. Frederick Natural killer cell tolerance: licensing and other mechanisms, In Advances in immunology 2009 Academic Press New York pp. 27-79
41. M.Y. Wayne, and K. Sungjin Licensing of natural killer cells by self-major histocompatibility complex class I Immunol Rev 214 2006 143 154
42. P.S. Woll, B. Grzywacz, and X. Tian Human embryonic stem cells differentiate into a unique population of natural killer cells with highly potent in vivo anti-tumor activity Blood 113 2009 6094 6101
43. S.A. Rosenberg, B.S. Packard, and P.M. Aebersold Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report New Engl J Med 320 1988 1418 1419
44. S.A. Rosenberg, N.P. Restifo, J.C. Yang, R.A. Morgan, and M.E. Dudley Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 8 2008 299 308
45. S.A. Rosenberg, M.T. Lotze, and J.C. Yang Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Ann Surg 210 1989 474 485
46. L. Ruggeri, M. Capanni, and E. Urbani Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100
47. J.S. Miller, Y. Soignier, and A. Panoskaltsis-Mortari Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 2005 3051 3057
48. H.G. Ljunggren, and K.J. Malmberg Prospects for the use of NK cells in immunotherapy of human cancer Nat Rev Immunol 7 2007 329 339
49. M. Schaffer, K.J. Malmberg, O. Ringdén, H.G. Ljunggren, and M. Remberger Increased infection-related mortality in kir-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation Transplantation 78 2004 1081 1085
50. D.W. Beelen, H.D. Ottinger, and S. Ferencik Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias Blood 105 2005 2594 2600
51. S. Giebel, F. Locatelli, and T. Lamparelli Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors Blood 102 2003 814 819
52. H.J. van der Vliet, H.B. Koon, and S.C. Yue Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer Clin Cancer Res 13 2007 2100 2108
53. F. Ghiringhelli, C. Ménard, F. Martin, and L. Zitvogel The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression Immunol Rev 214 2006 229 238
54. L. Li, L.N. Liu, S. Feller, C. Allen, and R. Shivakumar Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method Cancer Gene Therapy 17 2010 147 154
55. E.S. Ng, R.P. Davis, L. Azzola, E.G. Stanley, and A.G. Elefanty Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation Blood 106 2005 1601 1603
56. M. Pick, L. Azzola, A. Mossman, E.G. Stanley, and A.G. Elefanty Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor 2 in hematopoiesis Stem Cells 25 2007 2206 2214
57. A. Wilber, J.L. Linehan, and X. Tian Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer Stem Cells 25 2007 2919 2927
58. A. Giudice, and A. Trounson Genetic modification of human embryonic stem cells for derivation of target cells Cell Stem Cell 2 2008 422 433
59. M. Gropp, P. Itsykson, and O. Singer Stable genetic modification of human embryonic stem cells by lentiviral vectors Mol Ther 7 2003 281 287
60. J. Richard, S. Sindhu, T.N. Pham, J.P. Belzile, and E.A. Cohen HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing Blood 115 2010 1354 1363
61. T.F. Mselle, A.L. Howell, M. Ghosh, C.R. Wira, and C.L. Sentman Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12 J Virol 83 2009 11188 11195
62. A.S. Fauci, D. Mavilio, and S. Kottilil NK cells in HIV infection: paradigm for protection or targets for ambush Nat Rev Immunol 5 2005 835 843
63. G. Dotti, B. Savoldo, and M. Brenner Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?" Hum Gene Ther 20 2009 1229 1239
64. C. Carpenito, M.C. Milone, and R. Hassan Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Natl Acad Sci U S A 106 2009 3360 3365
65. C.S. Hinrichs, Z.A. Borman, L. Cassard, L. Gattinoni, and R. Spolski Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity Proc Natl Acad Sci U S A 106 2009 17469 17474
66. K.Q. Tran, J. Zhou, and K.H. Durflinger Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy J Immunother 31 2008 742 751
67. R.M. Marion, K. Strati, and H. Li Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells Cell Stem Cell 4 2009 141 154
68. R. Brentjens, R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain Treatment of chronic lymphocytic leukemia with genetically targeted autologous t cells: case report of an unforeseen adverse event in a phase I clinical trial Mol Ther 18 2010 666 668
69. R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, C.M. Laurencot, and S.A. Rosenberg Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 2010 843 851
70. L.L. Lanier Natural killer cell receptor signaling Curr Opin Immunol 15 2003 308 314
71. L.L. Lanier, C. Chang, H. Spits, and J.H. Phillips Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells and CD3 gamma, delta, epsilon complexes in fetal NK cells. Implications for the relationship of NK and T lymphocytes J Immunol 149 1992 1876 1880
72. M.H. Kershaw, J.A. Westwood, and L.L. Parker A phase I study on adoptive immunotherapy using gene-modified t cells for ovarian cancer Clin Cancer Res 12 2006 6106 6115
73. G.M. Bendle, C. Linnemann, and A.I. Hooijkaas Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy Nat Med 16 2010 565 570
74. L.M. Weiner, R. Surana, and S. Wang Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat Rev Immunol 10 2010 317 327
75. J. Stagg, J. Sharkey, and S. Pommey Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response Proc Natl Acad Sci U S A 105 2008 16254 16259
76. C.H. Martin, P.S. Woll, J.C. Zúñiga-Pflücker, and D.S. Kaufman Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells Blood 112 2008 2730 2737
77. R.N. La Motte-Mohs, E. Herer, and J.C. Zúñiga-Pflücker Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro Blood 105 2005 1431 1439
78. F. Timmermans, I. Velghe, and L. Vanwalleghem Generation of T cells from human embryonic stem cell-derived hematopoietic zones J Immunol 182 2009 6879 6888
79. M.H. Kershaw, M.W. Teng, M.J. Smyth, and P.K. Darcy Supernatural T cells: genetic modification of T cells for cancer therapy Nat Rev Immunol 5 2005 928 940